Stock Watch: Veklury Peaks And Leaves Gilead In The Lurch
The Pandemic Still Drags On Other Antiviral Sales
Veklury rescued Gilead’s weak underlying first-quarter performance. But the pandemic and its associated behavioral effects, as well as patent expiries, will continue to drag.
You may also be interested in...
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
Among equity investors there is concern about the impact of macroeconomic headwinds on second-quarter earnings. The first two big life sciences companies’ reports did nothing to alleviate those concerns.